問卷

TPIDB > Search Result

Search Result

篩選

List

51Cases

2025-03-01 - 2026-12-31

Phase I

Active
An open-label, multicenter, platform study evaluating the safety, tolerability, bioactivity, and pharmacokinetics of various intravitreal injection therapies in retinal diseases—APEX
  • Condition/Disease

    It is used to treat inflammatory secondary macular edema (MESI) and is being explored as a treatment option for other retinal vascular diseases such as diabetic macular edema (DME).

  • Test Drug

    KSI-101

Participate Sites
3Sites

Recruiting3Sites

2025-03-01 - 2029-03-01

Phase III

Active
A randomized, double-blind, placebo-controlled, multicenter phase 3 clinical trial evaluating the efficacy and safety of Ropeginterferon alfa-2b (P1101) in adult patients with pre-fibrotic/early primary myelofibrosis or marked primary myelofibrosis classified as low- or intermediate-risk 1 according to DIPSS Plus (HOPE-PMF): core trial and its extension trial.
  • Condition/Disease

    Clinically relevant complete hematologic response (CrCHR) at week 80, and symptom assessment indicators at week 80. CrCHR was defined as: 1. Platelet count ≤ 400 x 10^9/L, and 2. White blood cell (WBC) ≤ 10 x 10^9/L, and 3. Peripheral blood: Heme (Hgb) ≥ 10.0 g/dL, and 4. No major thrombotic events, and 5. No progression to secondary acute myeloid leukemia (AML). Symptom assessment indicators were defined as: 6. No worsening of clinical symptoms according to the MFSAF Total Symptom Score (TSS) version 4.0; no worsening of clinical symptoms was defined as: - If the baseline TSS score ≤ 10, then the TSS score remained ≤ 10; or - If the baseline TSS score > 10, then the TSS score did not increase by > 50%.

  • Test Drug

    Ropeginterferon alfa-2b (P1101)

Participate Sites
14Sites

Recruiting14Sites

2018-12-31 - 2026-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-01-31 - 2028-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2021-02-25 - 2024-06-05

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting7Sites

Terminated2Sites

2018-10-01 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting12Sites

2021-05-01 - 2025-12-31

Phase II/III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
14Sites

Recruiting12Sites

2021-08-31 - 2026-12-31

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Recruiting16Sites

2020-10-23 - 2021-10-08

Phase III

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2023-09-01 - 2028-02-29

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites